De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China-Reference-Cited by-同舟云学术

De‐escalation or discontinuation of tyrosine kinase inhibitor in patients with chronic myeloid leukemia: A multicentral, open‐label, prospective trial in China

Published:2022-09-19 Issue:4 Volume:3 Page:1220-1230
ISSN:2688-6146
Container-title:eJHaem
language:en
Short-container-title:eJHaem

Author:

Luo Jie¹^ORCID,Du Xin²,Lou Jin²,Wu Jianwei³,Ma Liping⁴,Huang Jixian⁵,Wang Liangtuo⁶,Tu Chuanqing⁷,Liu Zelin⁸,Chen Liya⁹,Tan Yaxian¹,Luo Dongmei¹,Liang Hanyin¹,Yin Changxin¹,Cao Rui¹,Zhou Xuan¹,Liu Qifa¹^ORCID,Liu Xiaoli¹,Xu Na¹

Affiliation:

1. Department of Hematology Nanfang Hospital Southern Medical University Guangzhou China

2. Department of Hematology, Shenzhen Second People's Hospital, The First Affiliated Hospital of Shenzhen University Shenzhen University School of Medicine Shenzhen China

3. Department of Hematology Jinan University Affiliated Jiangmen Hospital of Traditional Chinese Medicine Jiangmen Guangdong China

4. Department of Hematology, Sun Yat‐sen Memorial Hospital Sun Yat‐sen University Guangzhou China

5. Department of Hematology, Yuebei People's Hospital Shantou University Shaoguan Guangdong China

6. Department of Hematology People's hospital of Yang Jiang Yang Jiang Guangdong China

7. Department of Hematology, Bao' an District People Hospital The Second Affiliated Hospital of Shenzhen University Shenzhen China

8. Department of Hematology Huazhong University of Science and Technology Union Shenzhen Hospital (Nanshan Hospital) Shenzhen China

9. Department of Medical Quality Management Nanfang Hospital Southern Medical University Guangzhou China

Publisher

Wiley

Subject

General Earth and Planetary Sciences

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/jha2.550

Reference26 articles.

1. European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

2. Molecular response to imatinib in patients with chronic myeloid leukemia in Tanzania

3. Treatment-free remission in CML: who, how, and why?

4. Tyrosine Kinase Inhibitor Therapy Discontinuation for Patients with Chronic Myeloid Leukaemia in Clinical Practice

5. An alternative way – tyrosine kinase inhibitor (TKI) de-escalation – to discontinue TKIs in order to achieve treatment-free remission

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Kinetics of BCR::ABL1 transcript levels and molecular relapse after tyrosine kinase inhibitors discontinuation in chronic myeloid leukemia patients: preliminary results from the DES-CML study;Frontiers in Oncology;2024-05-08

2. The Italian Multicentric Randomized OPTkIMA Trial on Fixed vs Progressive Intermittent TKI Therapy in CML Elderly Patients: 3-Years of Molecular Response and Quality of Life Monitoring After Completing the Treatment Plan;Clinical Lymphoma Myeloma and Leukemia;2024-05

3. Peripheral lymphocyte subsets as predicting factors for molecular recurrence after imatinib discontinuation in a phase 2 imatinib discontinuation trial in patients with chronic myeloid leukemia;Hematology, Transfusion and Cell Therapy;2023-07

4. SOHO State of the Art Updates and Next Questions | Update on Treatment-Free Remission in Chronic Myeloid Leukemia (CML);Clinical Lymphoma Myeloma and Leukemia;2023-05

5. Successful treatment discontinuation in CML patients with full-dose and low-dose TKI: Results from real-world practice;Frontiers in Pharmacology;2023-01-23